Earnings Call Summary | Aclaris Therapeutics(ACRS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Aclaris Therapeutics(ACRS.US) Q1 2024 Earnings Conference
The following is a summary of the Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript:
以下是Aclaris Therapeutics, Inc.(ACRS)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Aclaris Therapeutics had $161 million in cash, cash equivalents and marketable securities at the end of Q1, down from $182 million at year-end, predominantly due to approximately $14 million in nonrecurring payments.
They are implementing cost containment measures and expect significantly reduced cash expenditure for the rest of the year.
The company is also seeking opportunities in business development to generate non-dilutive capital.
截至第一季度末,Aclaris Therapeutics拥有1.61亿美元的现金、现金等价物和有价证券,低于年底的1.82亿美元,这主要是由于大约1400万美元的非经常性付款。
他们正在实施成本控制措施,并预计今年剩余时间的现金支出将大幅减少。
该公司还在寻求业务发展机会,以产生非稀释性资本。
Business Progress:
业务进展:
Aclaris has decided to move the ATI-2138 drug into a proof-of-concept study for moderate to severe atopic dermatitis, based off positive data from Phase 1 clinical trials.
They are planning a 12-week phase 2 study with 15 patients for this new drug.
Aclaris believes the inhibition of the ITK pathway is a potential treatment for autoimmune diseases and is focusing development efforts in this direction.
The company retains rights to certain JAK inhibitors under development for alopecia, with royalty deals already signed with Lilly and Sun Pharma.
They are confident in their strategic approach to addressing the unmet needs in atopic dermatitis, buoyed by successful competition yet high numbers of patients not seeing desired results.
ATI-2138, the company's primary investigational drug, might have comparable efficacy to existing JAK inhibitors, but may differentiate in the safety profile, subject to further studies and approvals.
根据 1 期临床试验的积极数据,Aclaris 已决定将 ATI-2138 药物转入一项针对中度至重度特应性皮炎的概念验证研究。
他们计划对15名患者进行为期12周的2期研究,研究这种新药。
Aclaris认为,抑制ITK途径是治疗自身免疫性疾病的潜在方法,并正在将开发工作重点放在这个方向上。
该公司保留正在开发的某些用于脱发的JAK抑制剂的权利,已经与礼来公司和Sun Pharma签署了特许权使用费协议。
他们对解决特应性皮炎未得到满足的需求的战略方针充满信心,这得益于成功的竞争,但大量患者没有看到预期的效果。
ATI-2138 是该公司的主要研究药物,其疗效可能与现有的 JAK 抑制剂相当,但在安全性方面可能有所不同,尚待进一步的研究和批准。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。